For nearly three decades, Kid Risk, Inc. researchers and collaborators have contributed to the academic literature related to managing health systems and characterization of health economics. This work builds on our value of information approach that guides us to constantly evaluate the benefits and costs of information and our experience with hospital laboratory operations and clinical care. We continue to expand our efforts in this area as health systems become increasingly more complex, the embeded risks become less transparent, and the reimbursement structure moves towards measurable value-based care.

Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization

Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N

Lancet, 2024; 403(10441):2307-2316, doi:10.1016/S0140-6736(24)00850-X.

Health economic analysis of antiviral drugs in the global polio eradication endgame

Badizadegan K, Kalkowska DA, Thompson KM

Med Decis Making, 2023:272989x231191127. doi:10.1177/0272989x231191127.

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation

Kalkowsa DA, Wassilak SGF, Wiesen E, Estivariz CF, Burns CC, Badizadegan K, Thompson KM

Gates Open Res, 2023 [version 1; peer review: 1 approved].

Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2022. 21(11):1667-1674. doi:10.1080/14760584.2022.2128108.

Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative

Thompson K, Kalkowska D, Badizadegan K

Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1. [version 1; awaiting peer review]

Health economic analyses of secondary vaccine effects: a systematic review and policy insights

Thompson KM, Badizadegan K

Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.

An updated economic analysis of the global polio eradication initiative

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.

Health and economic outcomes associated with polio vaccine policy options: 2019–2029

Kalkowska DA, Thompson KM

Risk Anal, 2021; 41(2):364-375. doi:https://doi.org/10.1111/risa.13664.

No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]

Thompson KM, Kalkowska DA, Badizadegan K

Risk Anal, 2021; 41(2):389-392. doi:10.1111/risa.13671.

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States

Thompson KM, Kalkowska DA, Badizadegan K

Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.

Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America

Badizadegan K, Vanlandingham DM, Hampton W, Thompson KM

BMC Health Serv Res, 2020; 20(1):962. doi:10.1186/s12913-020-05815-0.

Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019

Thompson KM, Orenstein WA, Hinman AR

Vaccine, 2020; 38(9):2136-2143. doi:https://doi.org/10.1016/j.vaccine.2020.01.042.

An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches

Thompson KM, Orenstein WA, Hinman AR

Vaccine, 2020. doi:10.1016/j.vaccine.2020.04.044.

Valuing health outcomes: developing better defaults based on health opportunity costs

Ochalek J, Claxton K, Lomas J, Thompson KM

Expert Rev Pharmacoecon Outcomes Res, 2020:1-8. doi:10.1080/14737167.2020.1812387.

Potential Future Use, Costs, and Value of Poliovirus Vaccines

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):349-363. doi:10.1111/risa.13557.

Modeling pathology workload and complexity to manage risks and improve patient quality and safety

Vanlandingham DM, Hampton W, Thompson KM, Badizadegan K

Risk Anal, 2020; 40(2):421-434. doi:10.1111/risa.13393.

Characterising the costs of the global polio laboratory network: a survey-based analysis

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM

BMJ Open, 2019; 9(1):e023290. doi:10.1136/bmjopen-2018-023290.

Radiofrequency Interference in the Clinical Laboratory

Badizadegan ND, Greenberg S, Lawrence H, Badizadegan K

Am J Clin Pathol, 2019; 151(5):522-528. doi:10.1093/ajcp/aqy174.

Systematic review of the incremental costs of interventions that increase immunization coverage

Ozawa S, Yemeke TT, Thompson KM

Vaccine, 2018; 36(25):3641-3649. doi:10.1016/j.vaccine.2018.05.030.

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy

Duintjer Tebbens RJ, Thompson KM

Epidemiol Infect, 2017; 145(2):217-226. doi:10.1017/S0950268816002302.

Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use

Duintjer Tebbens RJ, Thompson KM

MDM Policy Pract, 2017; 2(1):2381468317697002. doi:10.1177/2381468317697002.

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers

Duintjer Tebbens RJ, Thompson KM

Vaccine, 2017; 35(31):3823-3833. doi:10.1016/j.vaccine.2017.05.090.

Systematic review of health economic analyses of measles and rubella immunization interventions

Thompson KM, Odahowski CL

Risk Anal, 2016; 36(7):1297-314. doi:10.1111/risa.12331.

The costs and valuation of health impacts of measles and rubella risk management policies

Thompson KM, Odahowski CL

Risk Anal, 2016; 36(7):1357-82. doi:10.1111/risa.12459.

The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management

Duintjer Tebbens RJ, Thompson KM

Future Microbiol, 2016; 11:1549-1561. doi:10.2217/fmb-2016-0126.

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes

Thompson KM, Duintjer Tebbens RJ

BMC Infect Dis, 2015; 15:374. doi:10.1186/s12879-015-1113-7.

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

Thompson KM, Duintjer Tebbens RJ

BMC Infect Dis, 2015; 15:376. doi:10.1186/s12879-015-1116-4.

An economic analysis of poliovirus risk management policy options for 2013-2052

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM

BMC Infect Dis, 2015; 15:389. doi:10.1186/s12879-015-1112-8.

Medical student knowledge, attitudes, and practices regarding immunization

Berera D, Thompson KM

J Vaccines Vaccin, 2015; 6(1):1000268. doi:10.4172/2157-7560.1000268.

Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention

Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL

Vaccine, 2013; 31 Suppl 2:B149-56. doi:10.1016/j.vaccine.2012.11.091.

Pediatric traumatic brain injury and radiation risks: a clinical decision analysis

Hennelly KE, Mannix R, Nigrovic LE, Lee LK, Thompson KM, Monuteaux MC, Proctor M, Schutzman S

J Pediatr, 2013; 162(2):392-7. doi:10.1016/j.jpeds.2012.07.018.

Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation

Thompson KM, Duintjer Tebbens RJ

Expert Rev Vaccines, 2012; 11(4):449-59. doi:10.1586/erv.11.195.

Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases

Thompson KM

ICU Management, 2012; 12(4):9-11. doi:N/A.

Research priorities for global measles and rubella control and eradication

Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM

Vaccine, 2012; 30(32):4709-16. doi:10.1016/j.vaccine.2012.04.058.

Group report: developing an eradication investment case

Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker D

In Disease Eradication in the 21st Century: Implications for Global Health, S.L. Cochi and W.R. Dowdle, Editors. 2011, MIT Press: Cambridge, MA. p. 133-148.

Economic evaluation of the benefits and costs of disease elimination and eradication initiatives

Thompson KM, Duintjer Tebbens RJ

In Disease Eradication in the 21st Century: Implications for Global Health, S.L. Cochi and W.R. Dowdle, Editors. 2011, MIT Press: Cambridge, MA. p. 115-130.

Value of information in nonfocal colonic biopsies

Badizadegan K, Thompson KM

J Pediatr Gastroenterol Nutr, 2011; 53(6):679-83. doi:10.1097/MPG.0b013e31822862d9.

Economic analysis of the global polio eradication initiative

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM

Vaccine, 2010; 29(2):334-43. doi:10.1016/j.vaccine.2010.10.026.

The risks, costs, and benefits of possible future global policies for managing polioviruses

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL

Am J Public Health, 2008; 98(7):1322-30. doi:10.2105/AJPH.2007.122192.

Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM

Risk Anal, 2008; 28(4):855-76. doi:10.1111/j.1539-6924.2008.01078.x.

Eradication versus control for poliomyelitis: an economic analysis

Thompson KM, Duintjer Tebbens RJ

Lancet, 2007; 369(9570):1363-1371. doi:10.1016/S0140-6736(07)60532-7.

Eradicating polio: the dollars and sense

Thompson KM

MedGenMed, 2007; 9(4):11.


Retrospective cost-effectiveness analyses for polio vaccination in the United States

Thompson KM, Duintjer Tebbens RJ

Risk Anal, 2006; 26(6):1423-40. doi:10.1111/j.1539-6924.2006.00831.x.

Body weight and water ingestion estimates for women in two communities in the Philippines: the importance of collecting site-specific data

Riederer AM, Thompson KM, Fuentes JM, Ford TE

Int J Hyg Environ Health, 2006; 209(1):69-80. doi:10.1016/j.ijheh.2005.08.002.

The costs of future polio risk management policies

Duintjer Tebbens RJ, Sangrujee N, Thompson KM

Risk Anal, 2006; 26(6):1507-31. doi:10.1111/j.1539-6924.2006.00842.x.

Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit

Wendler D, Belsky L, Thompson KM, Emanuel EJ

JAMA, 2005; 294(7):826-32. doi:10.1001/jama.294.7.826.

Value of information literature analysis: a review of applications in health risk management

Yokota F, Thompson KM

Med Decis Making, 2004; 24(3):287-98. doi:10.1177/0272989x04263157.

Integrated analysis: combining risk and economic assessments while preserving the separation of powers

Williams RA, Thompson KM

Risk Anal, 2004; 24(6):1613-23. doi:10.1111/j.0272-4332.2004.00554.x.

Estimation of tuberculosis risk on a commercial airliner

Ko G, Thompson KM, Nardell EA

Risk Anal, 2004; 24(2):379-88. doi:10.1111/j.0272-4332.2004.00439.x.

Validating benefit and cost estimates: the case of airbag regulation

Thompson KM, Segui-Gomez M, Graham JD

Risk Anal, 2002; 22(4):803-11. doi:10.1111/0272-4332.00070.

Genetic testing for lung cancer risk: if physicians can do it, should they?

Marcy TW, Stefanek M, Thompson KM

J Gen Intern Med, 2002; 17(12):946-51. doi:10.1046/j.1525-1497.2002.20378.x.

Emerging issues in vaccine economics: perspectives from the USA

Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL

Expert Rev Vaccines, 2002; 1(4):433-42. doi:10.1586/14760584.1.4.433.

Estimation of tuberculosis risk and incidence under upper room ultraviolet germicidal irradiation in a waiting room in a hypothetical scenario

Ko G, Burge HA, Nardell EA, Thompson KM

Risk Anal, 2001; 21(4):657-73. doi:10.1111/0272-4332.214142.

A dynamic programming approach to the efficient design of clinical trials

Claxton K, Thompson KM

J Health Econ, 2001; 20(5):797-822. doi:10.1016/S0167-6296(01)00093-5.

A scientific evaluation of health effects of two plasticizers used in medical devices and toys: A Report from the American Council on Science and Health

Koop CE, Juberg DR, Benedek EP, Brecher RW, Brent RL, Cole P, Corn M, Covello VV, Downes TW, Gad SC, Gold LS, Guengerich FP, Higginson J, Konemann WH, Lamb IJ, Lioy PJ, Lundberg GD, Thompson KM

MedGenMed, 1999:E14.

The cost-effectiveness of air bags by seating position

Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC

JAMA, 1997; 278(17):1418-25. doi:10.1001/jama.1997.03550170048031.

©2024 Kid Risk, Inc. All rights reserved.